Cases that Test Your Skills
The treatment-resistant catatonia patient
Ms. R develops severe catatonia after being hospitalized with agitation, delusions, and hallucinations. A benzodiazepine does not help. How would you treat her?
Case: Worsening psychosis
Ms. R, age 21, is admitted to our psychiatric facility while experiencing paranoid delusions and auditory hallucinations. Upon admission, she is agitated and her mood is labile.
Ms. R has 4 previous brief psychiatric admissions and was diagnosed with schizoaffective disorder, bipolar type and moderate mental retardation. Her family history is positive for psychiatric illness, as her mother was diagnosed with schizophrenia. Prior to admission, Ms. R was taking ziprasidone, 160 mg/d, and lithium, 450 mg/d, for 11 months. Both were discontinued during the first week of admission because Ms. R was not responding.
During this admission, the treating psychiatrist assesses Ms. R using the Schedules for Clinicians’ Interview in Psychiatry (SCIP), an instrument developed by the lead author (AA) for psychiatrists to use in conjunction with their routine clinical interviews in inpatient and outpatient settings (see Related Resources). The SCIP includes a 25-question screening section and a diagnostic section that consists of 7 modules that represent major psychiatric diagnoses defined by DSM and International Classification of Diseases criteria.1
During the first week of admission, we monitor Ms. R and administer haloperidol as needed, 10 mg total. Eight days after admission, she develops severe catatonia. On the catatonia scale of the SCIP, Ms. R scores the maximum on measures of immobility, catalepsy/waxy flexibility, and mutism (Table).
How would you treat Ms. R’s catatonia?
Patient’s catatonia symptoms: Response to pharmacotherapy
Lorazepam + risperidone
Risperidone oral only
Risperidone long-acting injection only
7 mg total over 7 days
Lorazepam: 4 mg/d Risperidone: 4 mg/d
37.5 mg every 2 weeks
Scores on SCIP catatonia scale:*
*Scale of 0 to 2, with 0=none, 1=less than half the time, and 2=more than half the time. Symptoms are evaluated over a 1-day period
†For this category, 0=none, 1=brief (usually <1 minute) episodes of ‘freezing’ in a position, and 2=episodes of ‘freezing’ in a position for >1 minute
SCIP: Schedules for Clinicians’ Interview in Psychiatry
The authors’ observations
DSM-IV-TR recognizes catatonia as a schizophrenia subtype, as a descriptor for mania and major depression, and as being caused by various medical conditions, such as neuroleptic malignant syndrome, encephalopathy, or renal failure.2 Kahlbaum initially described catatonia in 1873 as a brain disease characterized by motor abnormalities such as akinesia, rigidity, negativism, mutism, grimacing, posturing, catalepsy, waxy flexibility, and verbigerations.3 Catatonia is characterized by hypo- and hyperkinetic features. Catalepsy, stupor, rigidity, and catatonic posturing with waxy flexibility might alternate with violent catatonic excitement.4
Catatonia can be life-threatening; patients might not be able to eat or chew food, which puts them at risk for aspiration. Those with immobility might not move to urinate or defecate. During the first half of the 20th century, catatonia was documented in up to 50% of patients with schizophrenia.5 Since then, the incidence of catatonia has decreased, possibly the result of advances in psychopharmacology.6
Two days after Ms. R develops catatonia, we transfer her to a local hospital for evaluation to rule out a medical cause of her catatonic symptoms.
EVALUATION: No medical cause
At the hospital, physical examination, electroencephalography, drug screening, and liver and thyroid function tests are within normal limits, eliminating an organic cause of Ms. R’s catatonia. MRI of the head shows a 3-mm mass at the base of the infundibulum, which is unchanged from a prior MRI. Ms. R received 7 mg total of lorazepam over 4 days without relief of her catatonia. She is transferred back to our facility.
The authors’ observations
Benzodiazepines and ECT are effective treatments for catatonia.7 Benzodiazepines are considered first-line treatment because of their efficacy and favorable side-effect profile.7 Lorazepam frequently is used to treat catatonia in the short term.8 Long-term use of benzodiazepines, however, is associated with tolerance, addiction, and rebound phenomena.8,9
Patients with catatonia who do not respond to benzodiazepines may benefit from ECT.9 ECT can cause serious side effects, however, including memory impairment, confusion, delirium, and cardiac arrhythmias.10
Atypical antipsychotics may alleviate motor symptoms of catatonia by virtue of their 5-HT2A receptor antagonistic action.9 In 2 case reports, risperidone successfully treated catatonia.4,11 Kopala et al11 found risperidone, 4 mg/d, was effective in treating severe, first-episode catatonic schizophrenia in a neuroleptic-naive young man. This efficacy was sustained over a 3.5-year outpatient follow-up.
In another report, risperidone, 6 mg/d, effectively treated catatonia and prevented further episodes in a patient with schizophrenia who developed severe catatonia after receiving adequate treatment for Lyme disease with encephalitis.4 Two relapses of catatonic syndrome occurred when risperidone was reduced to 2 mg/d, and remission occurred after risperidone was increased to 6 mg/d. Risperidone’s antagonistic activity of the 5-HT2/D2 receptors may be relevant to its anticatatonic effect.12
Other atypical antipsychotics—ziprasidone and olanzapine—also have been shown to be effective in treating catatonia. Levy et al13 reported successful treatment of a catatonic state (with catalepsy, stupor, and mutism) using intramuscular ziprasidone followed by oral ziprasidone. A data analysis by Martenyi et al14 showed olanzapine to be effective in treating nonspecific signs and symptoms of catatonia, as measured by the Positive and Negative Syndrome Scale.
TREATMENT: Trying risperidone
Based on case reports showing risperidone’s efficacy for catatonia, we start Ms. R on risperidone, 4 mg/d, and lorazepam, 4 mg/d. Eight days later, her catatonic symptoms decrease substantially—she scores 2/6 on the SCIP catatonia scale (Table)—and she starts to talk with the staff.
We continue this regimen for 30 days, then discontinue lorazepam to avoid long-term side effects—such as dependence—and titrate risperidone to 8 mg/d. Ms. R continues to improve while taking risperidone only. Twenty-three days after stopping lorazepam, she is free of catatonic symptoms, scoring 0/6 on the SCIP catatonia scale.
We discharge Ms. R on risperidone. Because she has a history of medication nonadherence, we prescribe risperidone long-acting injection, 37.5 mg every 2 weeks, while continuing oral risperidone for 3 weeks after the first injection. She does well on this medication, experiencing no catatonic symptoms or adverse effects over the next 15 months as measured by the SCIP assessment.
The authors’ observations
This is the third case report in the literature to show that risperidone is effective in short- and long-term treatment of catatonia.4,11 Although Ms. R’s initial response can be attributed at least partially to lorazepam—which is known to be effective in treating catatonia—she continued to show improvement while taking risperidone only and remained free from catatonic symptoms for 15 months, until she was readmitted for reasons unrelated to catatonia.
We recommend using risperidone to treat catatonia in patients who do not respond to a benzodiazepine, especially those with other psychotic symptoms such as delusions or hallucinations. While administering risperidone, watch for long-term side effects, such as hyperlipidemia, weight gain, and diabetes. For catatonia in patients who cannot tolerate risperidone, consider olanzapine or ziprasidone.
- Schedules for Clinicians’ Interview in Psychiatry (SCIP). Available from Ahmed Aboraya, firstname.lastname@example.org.
- Valevski A, Loebl T, Keren T, et al. Response of catatonia to risperidone: two case reports. Clin Neuropharmacol. 2001;24(4):228-231.
- Van Den Eede F, Van Hecke J, Van Dalfsen A, et al. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry. 2005;20(5-6):422-429.
Drug brand names
- Haloperidol • Haldol
- Lithium • Eskalith, Lithobid
- Lorazepam • Ativan
- Olanzapine • Zyprexa
- Risperidone • Risperdal
- Risperidone long-acting injection • Risperdal Consta
- Ziprasidone • Geodon
The authors have no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.
1. Aboraya A, Tien A. Schedules for Clinicians’ Interviews in Psychiatry (SCIP): work in progress. International Journal of Mental Health and Addiction. Available at: http://www.ijma-journal.com/pdf/c01a09.pdf. Accessed February 4, 2009.
2. Diagnostic and statistical manual of disorders, 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
3. Kahlbaum KL. In: Levi Y, Pridon T, trans. Catatonia. Baltimore, MD: Johns Hopkins University Press; 1973.
4. Hesslinger B, Walden J, Normann C. Acute and long-term treatment of catatonia with risperidone. Pharmacopsychiatry. 2001;34(1):25-26.
5. Bleuler E. Dementia praecox. New York, NY: International University Press; 1950.
6. Blumer D. Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings. Compr Psychiatry. 1997;38(4):193-201.
7. Bush G, Fink M, Petrides G, et al. Catatonia. II Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;93(2):137-143.
8. Duggal HS, Gandotra G. Risperidone treatment of periodic catatonia. Can J Psychiatry. 2005;50(4):241-242.
9. Duggal HS. Risperidone treatment of febrile catatonia in first-episode psychosis. Gen Hosp Psychiatry. 2005;27(1):80-81.
10. Rudorfer M, Henry M, Sackeim H. Electroconvulsive therapy. In: Tasman A, Kay J, Lieberman JA, eds. Psychiatry: therapeutics. London, UK: John Wiley & Sons; 2003:167-203.
11. Kopala LC, Caudle C. Acute and longer-term effects of risperidone in a case of first-episode catatonic schizophrenia. J Psychopharmacol. 1998;12(3):314-317.
12. Poyurousky M, Bergman J, Weizman A. Risperidone in the treatment of catatonia in a schizophrenic patient. Isr J Psychiatry Relat Sci. 1997;34(4):323-324.
13. Levy WO, Nunez CY. Use of ziprasidone to treat bipolar-associated catatonia. Bipolar Disord. 2004;6(2):166-167.
14. Martenyi F, Metcalfe S, Schausberger B, et al. An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. J Clin Psychiatry. 2001;62(suppl 2):225-227.